Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Reverse Split ......

As R/S's are perceived as negative almost universally, it is something to avoid if possible.  Granted they CAN work, but if you don't NEED one, don't DO one, in my opinion.

That being said, if a settlement the type of cashendo that is being discussed actually occurs ($60M to $500M+ depending on who you want to listen to), it will almost certainly lead to additional license fees and cash flow that will provide a substantive capital fund by which PTSC can reduce the OS without an R/S.  Additional share buy backs will help.  But the right merger or acquisition process could accomplish the same result without any of the negatives associated with R/S.

By merge a resulting in a new entity being formed, brand new shares could be issued and PTSC shares and the other company's shares being converted to the new shares

Or by acquisition of an already listed company with PTSC shares being converted to the acquired company's shares at some ratio that would reduce the OS.

Both of these options are preferable to the R/S IMO, and certainly the M&A route is what the company has communicated is it's direction from a business standpoint, so both options are viable.  Secondly, if a successful settlement IS in the offiing, and it opens the gates to additional steady flow of licensing, all of this will take care of itself, IMO.  If a succesful settlement is NOT in the offiing, and the TX case and USPTO ruling go against PTSC, we'll look back on PTSC in a couple of years and see them executing reverse splits from OS levels twice what they are now.  I certainly won't be holding at that point! lol

Share
New Message
Please login to post a reply